Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

• Status: Not yet recruiting
• Trial end date: 2027-09-01

Summary

The goal of this clinical trial is to test the effect of tislelizumab treatment in patients with Hodgkin lymphoma. The main question it aims to answer is whether including a drug called tislelizumab in first-line treatment of Hodgkin lymphoma for patients age 60 years and older is effective and well-tolerated.

Participants will initially receive tislelizumab infusion every 21 days for 3 doses. After this a PET scan will be performed to assess the response. The subsequent treatment patients receive will depend on the following factors:

1. The lymphoma stage (early stage or advanced stage)

2. The presence or absence of specific high-risk features at the time of diagnosis

3. How well the lymphoma responds to the initial 3 doses of tislelizumab

• Phase: Phase 2

Details

• Lead Sponsor: University College, London
• Collaborator: BeiGene